Hantech Bio-Technology Co., Ltd. (1294) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Hantech Bio-Technology Co., Ltd. stock TWD 78.35, price TWD 45.10, upside +73.7%, quality 61 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
49‑month range 19.23 TWD – 483.55 TWD · fair‑value band 55.45 TWD – 107.92 TWD · the 45.10 TWD price screens below the 78.35 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Hantech Bio-Technology Co. in your weekly email
Every Wednesday you see whether Hantech Bio-Technology Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hantech Bio-Technology Co., Ltd., through its subsidiaries, engages in the manufacture, trade in, and distributes biotech foods, health foods, and Traditional Chinese Medicine skincare and beauty products in Taiwan and internationally.
Show moreShow less
The company offers OEM & ODM manufacturer of liquid, jelly, and gel-type health supplements. It also provides aluminum foil bag designs; and aluminum foil-packaged beverage production activities.
In addition, the company is involved in the manufacture of machinery and equipment; and trade in of health food raw materials.
It serves clients across both online and offline channels, including direct sales, micro-businesses, physical stores (pharmacies/drugstores/beauty shops), TV, radio, telemarketing centers, TV shopping, online shopping, and live-stream shopping.
Hantech Bio-Technology Co., Ltd. was founded in 2007 and is based in Changhua, Taiwan.
Stock analysis
Hantech Bio-Technology Co., Ltd. (1294) currently trades at 45.10 TWD, while our model-based Fair Value estimate is 78.35 TWD, implying the stock looks roughly 42% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 128.87 TWD per share, and 20 of the 26 models we run sit above the 45.10 TWD price.
Bear case: the Dividend Discount group reads lowest at 25.36 TWD, and 6 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 55.45 TWD (bear) to 107.92 TWD (bull), the price of 45.10 TWD sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Consumer Defensive sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Hantech Bio-Technology Co., Ltd. reported revenue of 779M TWD in FY2025 versus 240M TWD in FY2021, a compound +34.2%/yr. Reported net income was 139M TWD in FY2025, compounding +43.8%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap 1.7B TWD (≈ $50.3M) Micro · P/E ratio 12.3 · P/S ratio 1.91 · EPS (TTM) 3.68 TWD · Dividend yield 5.5% · Net margin 17.3% · Return on equity 18.4% · Return on assets (EBIT) 15.0% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 71 out of 100 (medium confidence).
What moves the price
The share trades about 38% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −1% fair-value upside, at 74%, 1294 screens cheaper than that median.
Fair Value models
Bear55.45 TWDFair Value 78.35 TWDBull107.92 TWD
Price 45.10 TWD · Upside +73.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (1.01 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+4.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+37.0%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+36.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+31.0%
Dividend (yield on the price)5.5%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 22%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+0.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about −1.4% a year for the price.
Compare Hantech Bio-Technology Co., Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Packaged Foods · 627 stocks
Beats the industry median on 12/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score61 · Above median
Fair Value upside+73.7% · Top 25%
Profitability
Return on equity (12 months)18.4% · Top 25%
Return on assets11.9% · Top 25%
Net margin (12 months)17.3% · Top 25%
Operating margin (12 months)20.5% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)16.9% · Top 25%
Dividend yield (12 months)5.5% · Top 25%
Balance sheet
Debt / equity0.08× · Below median
Valuation Multiplesvs Packaged Foods median · lower = cheaper
P/E (12 months)12.3× · Cheaper than median
P/B1.99× · Pricier than median
P/S (12 months)1.91× · Priciest 25%
Price / free cash flow (fiscal year)11.5× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Hantech Bio-Technology Co., Ltd. (1294) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 78.35 TWD versus a price of 45.10 TWD, about +74% upside (undervalued).
What is the fair value of 1294?
Our model-based fair value for Hantech Bio-Technology Co., Ltd. is 78.35 TWD (as of Nov 9, 2026), built from audited fundamentals. The current price: 45.10 TWD.
What is the quality score of 1294?
Hantech Bio-Technology Co., Ltd. has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hantech Bio-Technology Co., Ltd. (1294)?
Our model-based price target is the fair value of 78.35 TWD (as of Nov 9, 2026) from 26 valuation models. Cautious scenario 55.45 TWD, optimistic scenario 107.92 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Hantech Bio-Technology Co., Ltd. stock forecast for 2026?
Our models put fair value at 78.35 TWD, about +74% upside versus a price of 45.10 TWD (undervalued). Cautious scenario 55.45 TWD, optimistic scenario 107.92 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Hantech Bio-Technology Co., Ltd. (1294)?
Hantech Bio-Technology Co., Ltd. reported trailing-twelve-month revenue of about 865M TWD (latest available figure, as of Nov 9, 2026).
Does Hantech Bio-Technology Co., Ltd. pay a dividend?
Hantech Bio-Technology Co., Ltd. currently shows a dividend yield of 5.54% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Hantech Bio-Technology Co., Ltd. (1294) and when is the ex-dividend date?
Hantech Bio-Technology Co., Ltd. pays a dividend of 2.50 TWD per share a year, a dividend yield of 5.5%. The last ex-dividend date was Jul 3, 2026. The payout ratio is 67.9% of earnings. Free cash flow covers the dividend 1.58 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Hantech Bio-Technology Co., Ltd. (1294)?
For today's price to be fair in a discounted-cash-flow model, Hantech Bio-Technology Co., Ltd. would have to grow free cash flow by +0.2 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +34.2 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 1294 use?
Our models discount Hantech Bio-Technology Co., Ltd. at 13.3 %: a base by market capitalisation (micro), country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Hantech Bio-Technology Co., Ltd. that is +0.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.3 %) and the same formula as our fair value.
How much growth has Hantech Bio-Technology Co., Ltd. (1294) delivered so far?
Over the past 4 years revenue at Hantech Bio-Technology Co., Ltd. grew +34.2 % a year. The price currently implies free-cash-flow growth of +0.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Hantech Bio-Technology Co., Ltd. (1294) growing?
The median revenue growth in the sector is +2.0 % a year. That is the yardstick for the growth priced into Hantech Bio-Technology Co., Ltd. (+0.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Hantech Bio-Technology Co., Ltd. (1294)?
The free-cash-flow yield on the price is 10.54 %: that much free cash flow Hantech Bio-Technology Co., Ltd. produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Hantech Bio-Technology Co., Ltd. (1294)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hantech Bio-Technology Co., Ltd. it is 78.35 TWD per share (as of Nov 9, 2026), against a price of 45.10 TWD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Hantech Bio-Technology Co., Ltd. stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 1294 trades below its calculated fair value: price 45.10 TWD, fair value 78.35 TWD, a gap of about +74% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1294?
No. The price is what the market pays today (45.10 TWD); the fair value is what the company's own numbers justify (78.35 TWD). For Hantech Bio-Technology Co., Ltd. the two are 33.25 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Hantech Bio-Technology Co., Ltd. worth?
The market values Hantech Bio-Technology Co., Ltd. at about 1.7B TWD (market capitalisation, as of Nov 9, 2026). Per share that is 45.10 TWD; our models calculate a fair value of 78.35 TWD per share.
What do the bullish and bearish scenarios say about 1294?
Our models span a range for Hantech Bio-Technology Co., Ltd.: cautious scenario 55.45 TWD, base 78.35 TWD, optimistic 107.92 TWD per share (as of Nov 9, 2026, price 45.10 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1294?
Hantech Bio-Technology Co., Ltd. trades at a price-to-earnings ratio of 12.3 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 78.35 TWD is built from several models across several years. Other multiples: P/B 2.0, P/S 1.9, EV/EBITDA 6.9.
How solid is the balance sheet of Hantech Bio-Technology Co., Ltd. (1294)?
Balance-sheet figures for Hantech Bio-Technology Co., Ltd. (as of Nov 9, 2026): return on equity 18.4%, debt of 0.08 per unit of equity. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is 1294 from its 52-week high?
Hantech Bio-Technology Co., Ltd. trades at 45.10 TWD, about 38% below its 52-week high of 73.04 TWD and 2% above the low of 44.30 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 78.35 TWD is for.
Which stocks are comparable to Hantech Bio-Technology Co., Ltd.?
From the same area (Consumer Defensive) we also value Nestlé S.A, Danone S.A, Foshan Haitian Flavouring and Food Company, The Kraft Heinz Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hantech Bio-Technology Co., Ltd. stock attractive at the current price?
The data as of Nov 9, 2026: price 45.10 TWD, calculated fair value 78.35 TWD (+74%), Quality Score 61/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1294 calculated?
We run Hantech Bio-Technology Co., Ltd. through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 78.35 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Hantech Bio-Technology Co., Ltd. currently trades 42% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hantech Bio-Technology Co., Ltd. (1294)?
The closing price on Nov 9, 2026 was 45.10 TWD. Our model-based fair value is 78.35 TWD, about +74% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hantech Bio-Technology Co., Ltd. right now?
The price is below even our cautious bear case (55.45 TWD). The market is more pessimistic than our downside scenario. Solid quality (61/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (55.45 TWD to 107.92 TWD) leaves room in how you read the outcome.
Key figures of Hantech Bio-Technology Co., Ltd.
How large is the market capitalisation of Hantech Bio-Technology Co., Ltd. (1294)?
The market capitalisation of Hantech Bio-Technology Co., Ltd. is 1.7B TWD (≈ $50.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hantech Bio-Technology Co., Ltd. (1294)?
The price-to-sales ratio of Hantech Bio-Technology Co., Ltd. is 1.91 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hantech Bio-Technology Co., Ltd. (1294)?
Earnings per share at Hantech Bio-Technology Co., Ltd. are 3.68 TWD (price ÷ EPS = P/E 12.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hantech Bio-Technology Co., Ltd. (1294)?
The dividend yield of Hantech Bio-Technology Co., Ltd. is 5.5% (payout 67.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hantech Bio-Technology Co., Ltd. (1294)?
The net margin of Hantech Bio-Technology Co., Ltd. is 17.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hantech Bio-Technology Co., Ltd. (1294)?
The return on equity (ROE) of Hantech Bio-Technology Co., Ltd. is 18.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hantech Bio-Technology Co., Ltd. (1294)?
On an EBIT basis the return on assets of Hantech Bio-Technology Co., Ltd. is 15.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hantech Bio-Technology Co., Ltd. (1294)?
The operating margin of Hantech Bio-Technology Co., Ltd. is 20.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hantech Bio-Technology Co., Ltd. (1294)?
Revenue at Hantech Bio-Technology Co., Ltd. is growing +16.9% versus a year earlier (3y avg +37.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Hantech Bio-Technology Co., Ltd. (1294) carry?
The net debt of Hantech Bio-Technology Co., Ltd. is 118M TWD (fiscal year 2023, ≈ 0.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Hantech Bio-Technology Co., Ltd. in the live analysis
One click puts Hantech Bio-Technology Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 9, 2026